LEXICON PHARMACEUTICALS INC (LXRX)
US5288723027 - Common Stock
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference
THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following...
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant...
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies...
Lexicon Pharmaceuticals GAAP EPS of -$0.21 in-line, revenue of $0.16M misses by $1.9M (NASDAQ:LXRX)
Lexicon Pharmaceuticals reports Q3 GAAP EPS of -$0.21 in-line, but revenue of $0.16M misses by $1.9M.
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Commercial launch of INPEFA® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with...
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial...
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data...
INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients
As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting...
Lexicon Strengthens Management Team With Two New Executives
Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS,...
New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting
Presentations from four Lexicon-sponsored studies will highlight data supporting current and potential future use of sotagliflozin INPEFA®...
Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027
EQNX::TICKER_START (OTCPK:CNER),(NYSE:NVO),(NASDAQ:TNDM),(NASDAQ:DXCM),(NASDAQ:LXRX) EQNX::TICKER_END
Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027
/PRNewswire/ -- Recently, as the assorted global diabetes markets, such as drugs, devices and therapy continue to see an increased revenue yearly, so has the...
Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Abstracts for cost-effectiveness data and budget-impact model published in the Journal of Managed Care & Specialty Pharmacy (JMCP) INPEFA recently...
Lexicon to present data on cost-effectiveness of Inpefa on Tuesday (LXRX)
Lexicon Pharmaceuticals is scheduled to present data on the cost-effectiveness of its heart failure drug Inpefa at an managed care industry meeting on Tuesday. Read more here.
Friday 10/13 Insider Buying Report: LXRX, GLT
Lexicon Pharmaceuticals says Debbane buys 1M shares in company (NASDAQ:LXRX)
Raymond Debbane purchased 1M shares of Lexicon Pharmaceuticals, bringing his total holdings to 1.3M shares.
Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment of heart...
Why Shares of Lexicon Pharmaceuticals Are Up Tuesday
Express Scripts will give its clients access to Lexicon's first approved therapy.
Express Scripts to list Lexicon's Inpefa as preferred Medicare product (LXRX)
Lexicon Pharmaceuticals shares surged 13% after hours on news that Express Scripts plans to list its drug Inpefa as a preferred product on Medicare formularies. Read more here.
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
INPEFA recently approved by FDA for treatment of heart failure Express Scripts has determined that it will list INPEFA as a preferred product on Medicare...
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
Mr. Garner brings over 25 years of pharmaceutical industry experience...
Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of two randomized, double-blind, placebo-controlled Phase 3...
Commit To Purchase Lexicon Pharmaceuticals At $1, Earn 46% Annualized Using Options
Lexicon Pharmaceuticals CFO buys more shares (NASDAQ:LXRX)
Lexicon Pharmaceuticals (LXRX) on Thursday disclosed that President and CFO, Wade Jeffrey bought 10,000 common shares at $1.38 for a transaction value of $13,800.00.Wade Jeffrey now...
Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference
THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C....
Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase 2b dose...
Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023
INPEFA recently approved by FDA for treatment of heart failure...
Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure
Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of...